These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 30061443

  • 1. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C, Perego F, Borsoi L, Crosta V, Zanichelli A, Gidaro A, Tarricone R, Cicardi M.
    BMJ Open; 2018 Jul 30; 8(7):e022291. PubMed ID: 30061443
    [Abstract] [Full Text] [Related]

  • 2. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
    Bernstein JA, Tyson C, Relan A, Adams P, Magar R.
    J Manag Care Spec Pharm; 2020 Feb 30; 26(2):203-210. PubMed ID: 31841366
    [Abstract] [Full Text] [Related]

  • 3. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group.
    Immun Inflamm Dis; 2017 Mar 30; 5(1):29-36. PubMed ID: 28250922
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency.
    Zanichelli A, Mansi M, Azin GM, Wu MA, Periti G, Casazza G, Vacchini R, Suffritti C, Cicardi M.
    Allergy; 2015 Dec 30; 70(12):1553-8. PubMed ID: 26304015
    [Abstract] [Full Text] [Related]

  • 5. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I, IOS Study Group.
    Clin Exp Immunol; 2017 Apr 30; 188(1):148-153. PubMed ID: 27936514
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
    Hakl R, Kuklínek P, Krčmová I, Králíčková P, Freiberger T, Janků P, Vlková M, Litzman J.
    J Clin Immunol; 2018 Oct 30; 38(7):810-815. PubMed ID: 30280305
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.
    Bork K, Bernstein JA, Machnig T, Craig TJ.
    J Emerg Med; 2016 Apr 30; 50(4):567-80.e1. PubMed ID: 26826769
    [Abstract] [Full Text] [Related]

  • 9. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
    Grumach AS, Henriques MT, Bardou MLD, Pontarolli DA, Botha J, Correa M, IOS Brazil Study Group.
    An Bras Dermatol; 2022 Apr 30; 97(4):448-457. PubMed ID: 35654647
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH.
    J Allergy Clin Immunol Pract; 2017 Apr 30; 5(6):1671-1678.e2. PubMed ID: 28601641
    [Abstract] [Full Text] [Related]

  • 15. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Perrin A, Bouillet L, Andresen I, IOS Study Group.
    J Eur Acad Dermatol Venereol; 2017 Jul 30; 31(7):1214-1222. PubMed ID: 28370444
    [Abstract] [Full Text] [Related]

  • 16. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M, Horiuchi T, Ohsawa I, Andresen I, Fukunaga A.
    Allergol Int; 2021 Jan 30; 70(1):45-54. PubMed ID: 32919903
    [Abstract] [Full Text] [Related]

  • 17. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
    Toubi E, Kivity S, Graif Y, Reshef A, Botha J, Andresen I.
    Isr Med Assoc J; 2018 Apr 30; 20(4):227-232. PubMed ID: 29629730
    [Abstract] [Full Text] [Related]

  • 18. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.
    Lumry WR, Martinez-Saguer I, Yang WH, Bernstein JA, Jacobs J, Moldovan D, Riedl MA, Johnston DT, Li HH, Tang Y, Schranz J, Lu P, Vardi M, Farkas H, SAHARA study group.
    J Allergy Clin Immunol Pract; 2019 Apr 30; 7(5):1610-1618.e4. PubMed ID: 30682573
    [Abstract] [Full Text] [Related]

  • 19. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.
    Farkas H, Kőhalmi KV, Veszeli N, Zotter Z, Várnai K, Varga L.
    Allergy Asthma Proc; 2016 Apr 30; 37(2):164-70. PubMed ID: 26802388
    [Abstract] [Full Text] [Related]

  • 20. How satisfactory is on-demand icatibant from the patients' perspective in real life?
    Beyaz S, Demir S, Oztop N, Colakoglu B, Buyukozturk S, Gelincik A.
    Allergy Asthma Proc; 2022 Mar 01; 43(2):148-154. PubMed ID: 35317892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.